Gyo-Jeong Gu

Phenethyl isothiocyanate regulates inflammation through suppression of the TRIF-dependent signaling pathway of Toll-like receptors.

AIMS The aim of this study was to evaluate the therapeutic potential of the phenethyl isothiocyanate (PEITC) in Toll-like receptor (TLR) signaling pathways. MAIN METHODS To evaluate the cytotoxic nature of PEITC in RAW 264.7 cells, cytotoxicity was determined using the MTS cell viability assay. RAW264.7 cells were transfected with a nuclear factor-κB (NF-κB), interferon β (IFNβ) PRDIII-I, or interferon inducible protein-10 (IP-10) luciferase plasmid and then luciferase enzyme activities were determined by luciferase assay. The expression of inducible nitric oxide synthase (iNOS) and phosphorylation of interferon regulatory factor 3 (IRF3) were determined by Western blotting. The levels of IP-10 were determined with culture medium by using an IP-10 enzyme-linked immunosorbent assay (ELISA) kit. KEY FINDINGS PEITC suppressed the activation of IRF3 and the expression of IP-10 induced by lipopolysaccharide (LPS) or polyinosinic-polycytidylic acid (poly[I:C]). SIGNIFICANCE TLRs play an important role in the induction of innate immune responses for host defense against invading microbial pathogens. PEITC found in cruciferous vegetables has an effect on treatment of many chronic diseases. Our results suggest that beneficial effects of PEITC on chronic inflammatory diseases are mediated through modulation of Toll-interleukin-1 receptor domain-containing adapter inducing interferon-β (TRIF)-dependent signaling pathway of TLRs.

Suppression of inducible nitric oxide synthase expression induced by Toll-like receptor agonists by (E)-1-(2-(2-nitrovinyl)phenyl)pyrrolidine

Toll-like receptors (TLRs) recognize many pathogen-associated molecular patterns and induce innate immunity. TLR signaling pathways induce the activation of various transcription factors, such as nuclear factor-κB (NF-κB), leading to the induction of pro-inflammatory gene products, such as inducible nitric oxide synthase (iNOS). Here, we investigated the effect of an (E)-1-(2-(2-nitrovinyl)phenyl)pyrrolidine (NVPP), previously synthesized in our laboratory, on inflammation by modulating NF-κB activation and iNOS expression induced by TLR agonists in murine macrophages. NVPP suppressed NF-κB activation and iNOS expression induced by lipopolysaccharide (TLR4 agonist), polyriboinosinic polyribocytidylic acid (TLR3 agonist), and macrophage-activating lipopeptide 2kDa (TLR2 and TLR6 agonist). All the results suggest that NVPP is suitable for development as a new anti-inflammatory drug.

Suppressive effects of 1-[4-fluoro-2-(2-nitrovinyl)phenyl]pyrrolidine on the Toll-like receptor signaling pathways.

When various pathogens invade a host, toll-like receptors (TLRs) play a significant role in recognizing the pathogen-associated molecular patterns carried by the pathogens to induce innate immune reaction, followed by acquired immunity reaction. TLRs have two downstream signaling pathways, the myeloid differential factor 88 (MyD88)-dependent and toll-interleukin-1 receptor domain-containing adapter inducing interferon-β (TRIF)-dependent pathways. To evaluate the therapeutic potential of 1-[4-fluoro-2-(2-nitrovinyl)phenyl]pyrrolidine (FPP), previously synthesized in our laboratory, its effect on signal transduction via the TLR signaling pathways was examined. FPP inhibited the activation of nuclear factor-κB (NF-κB) and interferon regulatory factor 3 (IRF3) induced by TLR agonists, as well as inhibited the expression of cyclooxygenase-2, inducible nitric oxide synthase, and interferon inducible protein-10. FPP also inhibited the activation of NF-κB and IRF3 when induced by the overexpression of downstream signaling components of the TLRs. As a result, FPP has potential to become a new therapeutic drug for many inflammatory diseases.

Suppression of the TRIF-dependent Signaling Pathway of Toll-like Receptor by Triptolide

Toll-like receptors (TLRs) recognize specific patterns derived from invading microbial pathogens. TLR activation by microbial components triggers the activation of myeloid differential factor 88 (MyD88)- and tollinterleukin-1 receptor domain-containing adapter inducing interferon-β (TRIF)-dependent downstream signaling pathways, leading to the activation of nuclear factor-κB (NF-κB) and interferon regulatory factor 3 (IRF3). Triptolide (TP), an active ingredient of Tripterygium wilfordii Hook. F, has been reported to have positive effects on autoimmune and inflammatory diseases. To evaluate the therapeutic potential of TP, its effect on signal transduction via the TRIF-dependent pathway of TLRs induced by lipopolysaccharide (LPS) or polyinosinic-polycytidylic acid (poly[I:C]) was examined. TP inhibited NF-κB and IRF3 activation and IRF3 phosphorylation induced by LPS or poly[I:C]. TP also inhibited interferon-inducible genes such as, interferon inducible protein-10. These results suggest that TP can modulate TRIF-dependent signaling pathways of TLRs, and will become promising drug candidates in TLRs-based therapy in the future.

Eupatorium makinoi suppresses toll-like receptor signaling pathways

ABSTRACT Toll-like receptors (TLRs) recognize microbial molecules that are widely presented by pathogens and initiate the innate immune system. TLR signaling is divided into two different signaling pathways, the myeloid differential factor 88 (MyD88)- and Toll/interleukin-1 receptor domain-containing adapter inducing interferon-β (TRIF)-dependent pathways. Eupatorium makinoi, a plant species in Asteraceae, is used for medicinal purposes in China, Korea, and Japan. Through our previous research, we found that an ethanol extract of E. makinoi (EEM) suppresses inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression. In this study, we investigated the effect of EEM on TLRs signaling pathways. EEM suppresses NF-κB activation and iNOS and COX-2 expressions induced by TLR2 or TLR4 agonists. Also, EEM suppresses the activation of interferon (IFNs) regulatory factor 3 (IRF3) induced by TLR3 or TLR4 agonists. All results indicate that EEM suppresses myeloid differentiation primary-response protein 88 (MyD88) and TRIF-dependent signaling pathways of TLRs and the expressions of target genes derived from the activation of TLRs GRAPHICAL ABSTRACT

Eupartoium makinoi suppresses lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression

Inflammation is involved in numerous diseases including cancer. Inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) play important roles in the development of certain inflammatory diseases. Eupatorium makinoi, which belongs to a family of Asteraceae plants, is used medicinally in East Asia. We investigated the effects of an ethanol extract of E. makinoi (EEM) on nuclear factor-kappa B (NF-κB) activation and the expression of iNOS and COX-2 with lipopolysaccharide (TLR4 agonist) in murine macrophages. EEM suppressed NF-κB activation and iNOS and COX-2 expression induced by LPS. These results suggest that EEM may regulate TLR4 signalling pathways and this may be a useful strategy for anti-inflammatory therapies.

Suppression of Toll‐Like Receptor 4 Dimerization by 1‐[5‐Methoxy‐2‐(2‐nitrovinyl)phenyl]pyrrolidine

Toll‐like receptor 4 (TLR4) recognizes lipopolysaccharide (LPS) and triggers the activation of myeloid differention factor 88 (MyD88) and the Toll/interleukin‐1 receptor domain‐containing adapter, inducing interferon‐β (TRIF)‐dependent major downstream signaling pathways. To evaluate the therapeutic potential of 1‐[5‐methoxy‐2‐(2‐nitrovinyl)phenyl]pyrrolidine (MNP), previously synthesized in our laboratory, its effect on signal transduction via the TLR signaling pathways was examined. Here, we investigated whether MNP modulates the TLR4 signaling pathways and which anti‐inflammatory target in TLR4 signaling is regulated by MNP. MNP inhibited the activation of nuclear factor‐κB (NF‐κB) induced by LPS (TLR4 agonist), and it also inhibited the expression of cyclooxygenase‐2 and inducible nitric oxide synthase. MNP inhibited LPS‐induced NF‐κB activation by targeting TLR4 dimerization in addition to IKKβ. These results suggest that MNP can modulate the TLR4 signaling pathway at the receptor level to decrease inflammatory gene expression.

Suppression of the TRIF-dependent signaling pathway of Toll-like receptor by CDr10b in RAW264.7 macrophages

Toll-like receptors (TLRs) recognize distinct pathogen-associated molecular patterns and play a critical role in innate immune responses. TLR signaling pathways can be largely classified as either myeloid differential factor 88 (MyD88)- or toll-interleukin-1 receptor domain-containing adapter inducing interferon-β (TRIF)-dependent pathways. Compound of Designation red 10 binding (CDr10b) was synthesized to investigate its role in neuroinflammatory diseases. This study was conducted to determine whether CDr10b can affect TLR signaling pathways. CDr10b suppressed NF-κB activation as well as COX-2 and iNOS expression induced by TLR3 or TLR4 agonists. CDr10b also suppressed the activation of interferon regulatory factor 3 (IRF3) and the expression of interferon inducible protein-10 (IP-10) induced by TLR3 or TLR4 agonists. These results indicate that CDr10b can modulate the TRIF-dependent pathway of TLRs and has the potential to become a new therapeutic drug for chronic inflammatory diseases.

Carpesium abrotanoides extract inhibits inducible nitric oxide synthase expression induced by toll-like receptor agonists

Inflammation is a pathological and physiological process which is known to be involved in numerous diseases, while it is notable that a considerable proportion of chronic inflammatory diseases overlap with the development of cancer. One of the most important proteins for inflammatory responses is inducible nitric oxide synthase (iNOS). The present study investigated the effect of the extract of Carpesium abrotanoides L. (ECA) on inflammation by modulating iNOS expression induced by toll-like receptors (TLRs) agonists in murine macrophages. ECA suppressed iNOS expression induced by lipopolysaccharide (TLR4 agonist), macrophage-activating lipopeptide 2-kDa (TLR2 and TLR6 agonist), and polyriboinosinic polyribocytidylic acid (TLR3 agonist). All the results suggest that ECA can modulate TLR signaling pathways and subsequent chronic inflammatory responses.

CDr10b inhibits the expression of cyclooxygenase-2 and inducible nitric oxide synthase induced by lipopolysaccharide

The pathophysiological processes of inflammation can lead to a host of diseases, such as periodontitis, atherosclerosis, rheumatoid arthritis, and even cancer. The dysregulated inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) activation play important roles in the development of certain inflammatory diseases. Here, we investigated the effects of CDr10b which is originally developed for a microglia staining probe on inflammation, by modulating NF-κB activation and iNOS and COX-2 expression induced by lipopolysaccharide (LPS) in murine macrophages. The CDr10b suppressed NF-κB activation and iNOS and COX-2 expression induced by LPS. All the results suggest that CDr10b is a promising novel agent for the treatment of inflammatory diseases.